136 related articles for article (PubMed ID: 33745258)
1. PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population.
Karolova J; Radek M; Helman K; Spacek M; Trneny M; Klener P
Folia Biol (Praha); 2020; 66(4):117-122. PubMed ID: 33745258
[TBL] [Abstract][Full Text] [Related]
2. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
3. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
Zhang X; Lu H; Peng L; Zhou J; Wang M; Li J; Liu Z; Zhang W; Zhao Y; Zeng X; Lu L
Rheumatology (Oxford); 2022 Feb; 61(2):815-825. PubMed ID: 33930105
[TBL] [Abstract][Full Text] [Related]
4. Modulation of immune checkpoint molecule expression in mantle cell lymphoma.
Harrington BK; Wheeler E; Hornbuckle K; Shana'ah AY; Youssef Y; Smith L; Hassan Q; Klamer B; Zhang X; Long M; Baiocchi RA; Maddocks K; Johnson AJ; Byrd JC; Alinari L
Leuk Lymphoma; 2019 Oct; 60(10):2498-2507. PubMed ID: 30821551
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression,
Morales-Betanzos CA; Lee H; Gonzalez Ericsson PI; Balko JM; Johnson DB; Zimmerman LJ; Liebler DC
Mol Cell Proteomics; 2017 Oct; 16(10):1705-1717. PubMed ID: 28546465
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
7. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
[TBL] [Abstract][Full Text] [Related]
8. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
9. Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma.
Ameli F; Shajareh E; Mokhtari M; Kosari F
BMC Cancer; 2022 Aug; 22(1):848. PubMed ID: 35922773
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint molecule expression by B and T cell lymphomas in dogs.
Hartley G; Elmslie R; Dow S; Guth A
Vet Comp Oncol; 2018 Sep; 16(3):352-360. PubMed ID: 29380929
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
12. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
[TBL] [Abstract][Full Text] [Related]
13. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
[TBL] [Abstract][Full Text] [Related]
14. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.
Tanaka K; Miyata H; Sugimura K; Kanemura T; Hamada-Uematsu M; Mizote Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y; Tahara H
Cancer Sci; 2016 Jun; 107(6):726-33. PubMed ID: 27015293
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
16. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
[TBL] [Abstract][Full Text] [Related]
17. Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis.
Suszczyk D; Skiba W; Zardzewiały W; Pawłowska A; Włodarczyk K; Polak G; Tarkowski R; Wertel I
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232911
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
19. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.
Mathios D; Ruzevick J; Jackson CM; Xu H; Shah SR; Taube JM; Burger PC; McCarthy EF; Quinones-Hinojosa A; Pardoll DM; Lim M
J Neurooncol; 2015 Jan; 121(2):251-9. PubMed ID: 25349132
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]